Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy

Lung Cancer

Volumn 58, Issue 1, 2007, Pages 73-79

  Yoh, Kiyotaka ^a   Kubota, Kaoru ^a   Kakinuma, Ryutaro ^a   Ohmatsu, Hironobu ^a   Goto, Koichi ^a   Niho, Seiji ^a   Saijo, Nagahiro ^a   Nishiwaki, Yutaka ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Carboplatin; Chemotherapy; Non small cell lung cancer; Paclitaxel; Second line treatment; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; FAMOTIDINE; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPONATREMIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34548476301     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.04.015     Document Type: Article

References (17)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical, trials. BMJ 311 (1995) 899-909
2. Bunn Jr. P.A., and Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4 (1998) 1087-1100
3. Huisman C., Smit E.F., Giaccone G., and Postmus P.E. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 18 (2000) 3722-3730
4. Kelly K., Crowley J., Bunn Jr. P.A., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19 (2001) 3210-3218
5. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
6. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
7. Fossella F.V., DeVore R., Kerr R.N., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18 (2000) 2354-2362
8. Belani C.P., Lee J.S., Socinski M.A., et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 16 (2005) 1069-1075
9. Bunn Jr. P.A. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?. J Clin Oncol 20 (2002) 23-33
10. Hainsworth J.D., Thompson D.S., and Greco F.A. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13 (1995) 1609-1614
11. Sculier J.P., Berghmans T., Lafitte J.J., et al. A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy. Lung Cancer 37 (2002) 73-77
12. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
13. Shepherd F.A., Pereira J.R., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
14. Scagliotti G.V., De Marinis F., Rinaldi M., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20 (2002) 4285-4291
15. Ohe Y., Ohashi Y., Kubota K., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18 (2007) 317-323
16. Hotta K., Matsuo K., Ueoka H., et al. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 3852-3859
17. Pignon J.P., Tribodet H., Scagliotti G.V., et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4584 patients. Proc Am Soc Clin Oncol 24 (2006) 7008